Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Fri, 05/31/2024 – 14:04
Read more about Novartis Scembl…
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis
Fri, 05/31/2024 – 00:04
Read more about Novartis Phase III data confirm sustained efficacy and long-term s…
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Sat, 05/25/2024 – 12:19
Read more about Novartis atrasentan Phase III data show clinica…
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Sat, 05/25/2024 – 12:19
Read more about Novartis atrasentan Phase III data show clinica…
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis
Sat, 05/25/2024 – 12:04…
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
arcticnovartis
Thu, 05/16/2024 – 11:34
Read more about Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
…
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
arcticnovartis
Wed, 05/15/2024 – 16:02
Read more about Novartis highlights pioneering innovation in CML…
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
arcticnovartis
Mon, 05/06/2024 – 15:32
Read more about Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipel…
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
arcticnovartis
Tue, 04/23/2024 – 19:49
Read more about Novartis radioligand therapy Lutat…
